Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. in the Southern District of New York, concerning alleged misleading statements in the company's Offering Documents related to its initial public offering [1] Group 1: Allegations Against Neumora - The lawsuit claims that Neumora made materially false and/or misleading statements in its Offering Documents [2] - It is alleged that Neumora amended the Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2] - The complaint also states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [2] Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Group 3: Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected Neumora investors to contact them for more information [4] - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud affecting investors who purchased its common stock since September 15, 2023 [1][2]. Class Definition - The lawsuit aims to recover losses for all individuals or entities that acquired Neumora common stock based on the Offering Documents [2]. Case Details - The complaint alleges that Neumora made false statements and concealed critical information regarding its Phase Three Program and the Phase Two trials of its flagship therapeutic candidate, Navacaprant. Specifically, it claims that: - Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to demonstrate statistically significant improvement [3]. - A prespecified analysis was added to the Phase Two statistical analysis plan focusing on patients with moderate to severe MDD [3]. - The Phase Two Trials lacked adequate data, particularly concerning patient population size and gender ratio, which hindered accurate predictions for the KOASTAL-1 study results [3]. Next Steps - Investors who suffered losses in Neumora Therapeutics, Inc. during the relevant timeframe have until April 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements and failure to disclose critical information regarding its clinical trials, particularly related to its flagship therapeutic candidate, Navacaprant [3]. Group 1: Legal Action and Investor Information - The Portnoy Law Firm is representing investors who purchased Neumora common stock starting from September 15, 2023, and they have until April 7, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the law firm for a complimentary case evaluation and to discuss their legal rights regarding potential claims to recover losses [2]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora altered the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [3]. - The company modified the Phase Two statistical analysis plan by introducing a prespecified analysis focused on patients with moderate to severe MDD, which raises concerns about the validity of the trial results [3]. - There were significant deficiencies in the Phase Two trials, particularly regarding patient population size and the male-to-female ratio, which complicates the prediction of outcomes for the KOASTAL-1 study [3].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding its clinical trials and the efficacy of its flagship therapeutic candidate, Navacaprant [4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals or entities who purchased Neumora common stock during the class period starting on or about September 15, 2023 [3]. - The deadline for shareholders to register for the class action is April 7, 2025, and they are encouraged to register to monitor the case's progress [5]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [4]. - It is claimed that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [4]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors' rights against deceit and fraud [6]. - The firm emphasizes its commitment to ensuring responsible business practices and seeks recovery for investors who suffered losses due to misleading statements by companies [6].

Core Viewpoint - Rosen Law Firm is urging investors of Neumora Therapeutics, Inc. to secure legal counsel before the April 7, 2025 deadline for a securities class action related to the company's IPO in September 2023 [1][2]. Group 1: Legal Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 7, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that the Offering Documents contained false or misleading statements, including the necessity for Neumora to amend trial criteria to justify its Phase Three Program [5]. - It is claimed that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [5].

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. for allegedly making materially false and misleading statements in its Offering Documents related to its initial public offering [1] Group 1: Allegations Against Neumora - The lawsuit claims that Neumora amended its Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2] - It is alleged that Neumora added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2] - The complaint states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which affected the predictability of the KOASTAL-1 study results [2] Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3] - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]

NEW YORK, March 30, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm. Follow us for updates ...

If you suffered Neumora losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/neumora-therapeutics-inc? utm_source=PR&utm_medium=link&utm_campaign=nma&mktm=r You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Neumora Therapeutics, Inc. about the April 7, 2025 deadline to join a securities class action lawsuit related to the company's September 2023 IPO [1][2]. Group 1: Class Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that the Offering Documents contained false or misleading statements, including the necessity for Neumora to amend trial criteria to justify its Phase Three Program [5]. - It is claimed that Neumora added a prespecified analysis to the Phase Two statistical analysis plan to focus on patients with moderate to severe major depressive disorder [5]. - The lawsuit also states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, impacting the predictability of the KOASTAL-1 study results [5].

NEW YORK, March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or tr ...